Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
241.66
+0.92 (0.38%)
Sep 21, 2026, 4:00 PM EDT - Market closed

Jazz Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $290.6. The average 1-year stock price forecast is 20.25% higher than the current stock price, while the lowest is $225 (-6.89%) and the highest is $337 (+39.45%).

Price Target: $290.6 (+20.25%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$225$290.6$299.5$337
Change-6.89%+20.25%+23.93%+39.45%

Analyst Ratings

The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy91010111111
Buy677777
Hold211122
Sell011100
Strong Sell000000
Total171919202020

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Reiterates
$315$337
BuyReiterates$315$337+39.45%Sep 14, 2026
Barclays
Barclays
Buy
Maintains
$270$271
BuyMaintains$270$271+12.14%Sep 10, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$310
BuyReiterates$310+28.28%Sep 9, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$300
BuyMaintains$300+24.14%Sep 1, 2026
Truist Financial
Truist Financial
Buy
Maintains
n/a
BuyMaintainsn/an/aSep 1, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.72B
from 4.27B
Increased by 10.65%
Revenue Next Year
5.01B
from 4.72B
Increased by 6.03%
EPS This Year
25.03
from 8.38
Increased by 198.72%
EPS Next Year
25.77
from 25.03
Increased by 2.97%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.09B3.66B3.83B4.07B4.27B4.72B
Revenue Growth
30.91%18.26%4.78%6.12%4.88%10.65%
Gross Profit
2.88B3.39B3.55B3.76B3.91B4.26B
Gross Margin
92.97%92.70%92.59%92.36%91.67%90.16%
Operating Income
475.26M839.14M816.23M864.14M1.02B2.12B
Net Income
-329.67M-224.06M414.83M560.12M-356.15M1.00B
EPS
----8.3825.03
EPS Growth
-----59.90%198.72%
Forward PE
8.238.546.295.727.679.65
Free Cash Flow
----1.30B1.50B
No. Analysts
-----19
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.8B
Avg4.7B
Low4.7B

Revenue Growth

Revenue Growth202620272028
High
12.8%
Avg
10.6%
Low
9.2%

EPS Forecast

EPS202620272028
High26.89
Avg25.03
Low23.99

EPS Growth

EPS Growth202620272028
High
220.9%
Avg
198.7%
Low
186.3%